These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9864235)

  • 1. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.
    Yang C; Collins WE; Sullivan JS; Kaslow DC; Xiao L; Lal AA
    Infect Immun; 1999 Jan; 67(1):342-9. PubMed ID: 9864235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
    Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
    Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.
    Collins WE; Kaslow DC; Sullivan JS; Morris CL; Galland GG; Yang C; Saekhou AM; Xiao L; Lal AA
    Am J Trop Med Hyg; 1999 Mar; 60(3):350-6. PubMed ID: 10466960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of adjuvants on murine immune responses against the C-terminal 19 kDa fragment of Plasmodium vivax merozoite surface protein-1 (MSP-1).
    Yang C; Collins WE; Xiao L; Patterson PS; Reed RC; Hunter RL; Kaslow DC; Lal AA
    Parasite Immunol; 1996 Nov; 18(11):547-58. PubMed ID: 9226693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.
    Sachdeva S; Ahmad G; Malhotra P; Mukherjee P; Chauhan VS
    Infect Immun; 2004 Oct; 72(10):5775-82. PubMed ID: 15385477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route.
    Bargieri DY; Rosa DS; Lasaro MA; Ferreira LC; Soares IS; Rodrigues MM
    Mem Inst Oswaldo Cruz; 2007 Jun; 102(3):313-7. PubMed ID: 17568936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax.
    Collins WE; Sullivan JS; Morris CL; Galland GG; Jue DL; Fang S; Wohlhueter R; Reed RC; Yang C; Hunter RL; Lal AA
    Am J Trop Med Hyg; 1997 Feb; 56(2):200-10. PubMed ID: 9080881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the Plasmodium vivax merozoite surface protein 1 paralog in the induction of naturally acquired antibody and memory B cell responses.
    Min HMK; Changrob S; Soe PT; Han JH; Muh F; Lee SK; Chootong P; Han ET
    Malar J; 2017 Aug; 16(1):354. PubMed ID: 28854974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
    Near KA; Stowers AW; Jankovic D; Kaslow DC
    Infect Immun; 2002 Feb; 70(2):692-701. PubMed ID: 11796601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.
    Dutta S; Kaushal DC; Ware LA; Puri SK; Kaushal NA; Narula A; Upadhyaya DS; Lanar DE
    Infect Immun; 2005 Sep; 73(9):5936-44. PubMed ID: 16113314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
    Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
    Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria.
    Perera KL; Handunnetti SM; Holm I; Longacre S; Mendis K
    Infect Immun; 1998 Apr; 66(4):1500-6. PubMed ID: 9529073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
    Valderrama-Aguirre A; Quintero G; Gómez A; Castellanos A; Pérez Y; Méndez F; Arévalo-Herrera M; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):16-24. PubMed ID: 16291762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
    Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
    Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.
    Egan AF; Blackman MJ; Kaslow DC
    Infect Immun; 2000 Mar; 68(3):1418-27. PubMed ID: 10678955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
    Kaushal DC; Kaushal NA; Narula A; Kumar N; Puri SK; Dutta S; Lanar DE
    Indian J Biochem Biophys; 2007 Dec; 44(6):429-36. PubMed ID: 18320841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.
    Cavanagh DR; Kocken CH; White JH; Cowan GJ; Samuel K; Dubbeld MA; Voorberg-van der Wel A; Thomas AW; McBride JS; Arnot DE
    PLoS One; 2014; 9(1):e83704. PubMed ID: 24421900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.